Immunovant’s $450M private placement; Biomea becomes an obesity biotechnews2025-01-13T16:17:53+00:00January 13th, 2025|Endpoints News|
Stemson Therapeutics shutters; Insilico teams up again with Menarininews2025-01-10T15:45:09+00:00January 10th, 2025|Endpoints News|
Numab extends its Series C; AnaCardio raises $19M for its heart failure drugnews2025-01-09T15:19:43+00:00January 9th, 2025|Endpoints News|
Sana’s stock soars on new cell therapy data; UniQure’s $75M offeringnews2025-01-08T16:12:04+00:00January 8th, 2025|Endpoints News|
Novo Nordisk partners with Variant Bio; Aviceda raises $207M in Series Cnews2025-01-07T15:39:33+00:00January 7th, 2025|Endpoints News|
I-Mab stops work on CD73; Citius to pursue ‘strategic’ optionsnews2025-01-06T15:56:51+00:00January 6th, 2025|Endpoints News|
Hutchmed’s divestiture; Xgene reports Phase 2b win for non-opioid pain drugnews2025-01-02T15:43:21+00:00January 2nd, 2025|Endpoints News|
J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA appnews2024-12-27T15:48:02+00:00December 27th, 2024|Endpoints News|
PDUFAs for Tonix and Nuvation; Sanofi vaccine partnership; RAPT allergy dealnews2024-12-23T14:56:45+00:00December 23rd, 2024|Endpoints News|
Idorsia’s Tryvio deal delay; Galectin’s liver drug disappointsnews2024-12-20T15:16:16+00:00December 20th, 2024|Endpoints News|
